These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 9210685)

  • 1. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects.
    Chien SC; Chow AT; Natarajan J; Williams RR; Wong FA; Rogge MC; Nayak RK
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1562-5. PubMed ID: 9210685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
    Chien SC; Wong FA; Fowler CL; Callery-D'Amico SV; Williams RR; Nayak R; Chow AT
    Antimicrob Agents Chemother; 1998 Apr; 42(4):885-8. PubMed ID: 9559801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of oral levofloxacin in human immunodeficiency virus-infected individuals receiving concomitant zidovudine.
    Chien SC; Chow AT; Rogge MC; Williams RR; Hendrix CW
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1765-9. PubMed ID: 9257757
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses.
    Chien SC; Rogge MC; Gisclon LG; Curtin C; Wong F; Natarajan J; Williams RR; Fowler CL; Cheung WK; Chow AT
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2256-60. PubMed ID: 9333057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of food and sucralfate on a single oral dose of 500 milligrams of levofloxacin in healthy subjects.
    Lee LJ; Hafkin B; Lee ID; Hoh J; Dix R
    Antimicrob Agents Chemother; 1997 Oct; 41(10):2196-200. PubMed ID: 9333047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers.
    Chow AT; Fowler C; Williams RR; Morgan N; Kaminski S; Natarajan J
    Antimicrob Agents Chemother; 2001 Jul; 45(7):2122-5. PubMed ID: 11408234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levofloxacin pharmacokinetics in children.
    Chien S; Wells TG; Blumer JL; Kearns GL; Bradley JS; Bocchini JA; Natarajan J; Maldonado S; Noel GJ
    J Clin Pharmacol; 2005 Feb; 45(2):153-60. PubMed ID: 15647407
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and safety of high-dose and extended-interval regimens of levofloxacin in human immunodeficiency virus-infected patients.
    Piscitelli SC; Spooner K; Baird B; Chow AT; Fowler CL; Williams RR; Natarajan J; Masur H; Walker RE
    Antimicrob Agents Chemother; 1999 Sep; 43(9):2323-7. PubMed ID: 10471591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of ciprofloxacin XR (1000 mg) versus levofloxacin (500 mg) in plasma and urine of male and female healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Tischmeyer U; Wagenlehner C; Sörgel F; Dalhoff A; Naber KG
    Int J Antimicrob Agents; 2006 Jan; 27(1):7-14. PubMed ID: 16343856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of intravenous and oral levofloxacin in critically ill adults in a medical intensive care unit.
    Rebuck JA; Fish DN; Abraham E
    Pharmacotherapy; 2002 Oct; 22(10):1216-25. PubMed ID: 12389872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection.
    Goodwin SD; Gallis HA; Chow AT; Wong FA; Flor SC; Bartlett JA
    Antimicrob Agents Chemother; 1994 Apr; 38(4):799-804. PubMed ID: 8031049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection.
    Preston SL; Drusano GL; Berman AL; Fowler CL; Chow AT; Dornseif B; Reichl V; Natarajan J; Wong FA; Corrado M
    Antimicrob Agents Chemother; 1998 May; 42(5):1098-104. PubMed ID: 9593134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects.
    Gotfried MH; Danziger LH; Rodvold KA
    Chest; 2001 Apr; 119(4):1114-22. PubMed ID: 11296178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tear concentrations of levofloxacin following topical administration of a single dose of 0.5% levofloxacin ophthalmic solution in healthy volunteers.
    Raizman MB; Rubin JM; Graves AL; Rinehart M
    Clin Ther; 2002 Sep; 24(9):1439-50. PubMed ID: 12380635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections.
    Furlanut M; Brollo L; Lugatti E; Di Qual E; Dolcet F; Talmassons G; Pea F
    J Antimicrob Chemother; 2003 Jan; 51(1):101-6. PubMed ID: 12493793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentrations in plasma, urinary excretion and bactericidal activity of levofloxacin (500 mg) versus ciprofloxacin (500 mg) in healthy volunteers receiving a single oral dose.
    Wagenlehner FM; Kinzig-Schippers M; Sörgel F; Weidner W; Naber KG
    Int J Antimicrob Agents; 2006 Dec; 28(6):551-9. PubMed ID: 17101261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of traditional Chinese medicines on pharmacokinetics of levofloxacin.
    Hasegawa T; Yamaki K; Muraoka I; Nadai M; Takagi K; Nabeshima T
    Antimicrob Agents Chemother; 1995 Sep; 39(9):2135-7. PubMed ID: 8540731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses.
    Chow AT; Chen A; Lattime H; Morgan N; Wong F; Fowler C; Williams RR
    J Clin Pharm Ther; 2002 Apr; 27(2):143-50. PubMed ID: 11975700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age and sex effects on the pharmacokinetics of linezolid.
    Sisson TL; Jungbluth GL; Hopkins NK
    Eur J Clin Pharmacol; 2002 Jan; 57(11):793-7. PubMed ID: 11868801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.